Balance Sheet (Annual)

GBCS / Global Healthcare REIT, Inc. Short Interest

GBCS / Global Healthcare REIT, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Assets
  Property Plant And Equipment Net 2,543 8,089 40,259 39,742 36,163 36,380
  Cash And Cash Equivalents At Carrying Value 492 1,180 534 - 578 155
  Restricted Cash And Cash Equivalents At Carrying Value - 308 904 542 581 818
  Accounts Receivable Net - - - - - 88
  Trading Securities - - - - - 243
  Prepaid Expense And Other Assets - - - - 217 546
  Assets 3,846 12,552 46,478 41,777 37,544 38,230
Liabilities And Stockholders Equity
  Liabilities
    Debt Current - - - - 31,663 34,282
    Debt Related Parties Net - - - - 375 840
    Accounts Payable And Accrued Liabilities Current And Noncurrent - - - - - 350
    Accounts Payable Related Parties Current And Noncurrent - - - - 97 93
    Dividends Payable Current And Noncurrent - - - - - 8
    Derivative Liabilities - - - - 246 95
    Security Deposit Liability - 25 177 30 30 280
    Liabilities 2,099 7,661 38,056 37,181 33,010 35,948
    Commitments And Contingencies - - - - - -
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Stockholders Equity
      Preferred Stock Value - - - - - -
      Common Stock Value 343 728 1,082 1,112 1,251 1,315
      Additional Paid In Capital 15,074 3,769 8,541 8,979 8,707 9,423
      Retained Earnings Accumulated Deficit -14,771 -687 213 -4,840 -6,022 -9,048
      Stockholders Equity 1,747 5,017 10,611 6,027 4,713 2,465
      Minority Interest - -126 -2,189 -1,432 -178 -183
    Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1,747 4,891 8,422 4,595 4,534 2,282
  Liabilities And Stockholders Equity 3,846 12,552 46,478 41,777 37,544 38,230

Peers - Real Estate Investment Trusts (6798)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 37953J107